Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Ocrelizumab Treatment in Rheumatoid Arthritis
jRCT2080220736Phase 3
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- May 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ocrelizumab in rheumatoid arthritis (RA), sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
ocrelizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2080220736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220736.